Akeso

康方生物积极寻求战略合作，推动创新药物的开发和商业化，包括在中国和全球范围内的共同研发、合作和许可。

依达方是康方生物自主研发的全球首个PD-1/VEGF双特异性抗肿瘤药物，通过同时靶向PD-1和VEGF实现协同抗肿瘤效果，突破了传统单靶点的局限。

The company’s production system meets NMPA, FDA, and EMA requirements, supporting drug development from discovery to commercial production, with regular audits to ensure GMP compliance.

康方生物利用AI技术和多项平台（如Tetrabody双抗、Dual-Shield ADC、Tissue-Smart siRNA等）提升原创新药开发能力，实现多领域的创新突破。

Kanghong Biotech (HKEX: 9926) announced that its globally first-in-class tumor immunotherapy 2.0 cornerstone bispecific drug, Yvox (brand name: Yidafang), showed perioperative treatment results for resectable non-small cell lung cancer (NSCLC) in a phase II clinical trial published in *Nature Medicine*.

The NMPA’s Center for Drug Evaluation (CDE) included Kanghong Biotech’s (HKEX: 9926) globally first-in-class tumor immunotherapy 2.0 bispecific drug, Yvox, in its priority review for first-line treatment of locally advanced or metastatic biliary tract cancer (BTC) combined with chemotherapy.

The company monitors production and testing processes, oversees quality activities like deviation investigations and CAPA measures, and manages validation, training, and quality analysis while participating in drafting and reviewing documents and records.

康方生物负责开发爱达罗/依若奇单抗（已在26个国家纳入医保）和古莫奇单抗（IL-17，预计26年上市）。

Kanghong Biotech built its ACE Platform for comprehensive new drug research and development since 2012, establishing a core R&D innovation system with Tetrabody dual/multi-antibody technology, Dual-Shield ADC, Dual-Lock TCE, Tissue-Smart siRNA, cell therapy, and Flex-Nano mRNA.

Zhengda Tianqing Kanghong (Shanghai) Biopharmaceutical Technology Co., Ltd. is a joint venture between Kanghong Biotech (HKEX: 9926) and China National Biotec Group’s (HKEX: 1177) Zhengda Tianqing Pharmaceutical Group. The company develops biopharmaceuticals, commercializes research outcomes, and provides technology transfer and contract manufacturing. It focuses on the anti-PD-1 monoclonal antibody Paianplimab injection (brand name: Anike) for tumor immunotherapy.

Founded in 2012, Kanghong Biotech (HKEX: 9926) focuses on pioneering or best-in-class innovative biopharmaceuticals. It listed on the Hong Kong Stock Exchange’s main board in April 2020.

Kanghong Biotech’s globally first-in-class PD-1/VEGF bispecific antibody, Idavol (Yvox injection), received NMPA approval for its third indication: first-line treatment of late-stage squamous non-small cell lung cancer (sq-NSCLC) combined with chemotherapy.

康方生物由国际化团队创建，专注于肿瘤、自身免疫等重大疾病领域，并建立了以AI、双抗、ADC等技术为核心的研发创新体系和国际化GMP生产体系。

康方生物由国际化团队创建，专注于肿瘤、自身免疫等重大疾病领域，并建立了以AI、双抗、ADC等技术为核心的研发创新体系和国际化GMP生产体系。

康方生物制定隐私政策，说明如何收集和使用访问者的个人信息。